🌻We’re preparing #TumorBoardTuesday!
🧑🔬Join Dr Maryam Lustberg & Dr Adriana Kahn 08.01.23 8pm ET, for a walk through TNBC tx while pt on IS for #Crohns
🌻Don’t miss this essential MDT chat!
🧠Grab FREE #CME credits
👉🏽Visit integrityce.com/TBT2023 for more info
@JohnEbbenMDPhD @MPishvaian #OncoDon #PrecisionMedicine #Oncology #IBD #PrecisionOncology #BreastCancer #Cancer
🔥 #TumorBoardTuesday is a must-attend!
🧑🔬Join @marklewismd @CatherineaOC 07.25.23 8pm ET as they explore differentiating midgut & #PNETs
🔥Be part of an insightful discussion!
🧠Get FREE #CME credits as we finalize the case
👉🏽Visit integrityce.com/TBT2023 for more info #OncoDon #GastroDon
#PrecisionMedicine #Oncology #Pancreas #NETs
#NeuroendocrineTumor @MPishvaian @JohnEbbenMDPhD @EmpoweringPts9 @tumorboard @tumor
I just had a flashback of our orientation to MS3 after having completed my PhD.
Nice EM doc presenting some cases to get us back in the groove.
By the time I dug what “IVC” meant for the first case from the deep recesses of my brain, “we” were on the fourth case.
Happy Holidays from The Laboratory of Molecular Radiotherapy!
Great having the crew together for a showcase of foods and drinks from around the world!
What say ye #radonc?! Did we pin down what causes radiation fatigue?
β-Endorphin mediates radiation therapy fatigue https://www.science.org/doi/10.1126/sciadv.abn6025
Did you see this yet?
Abstract. Purpose: Immune checkpoint therapy (ICT) is currently ineffective in a majority of patients. Tumor drug exposure measurements can provide vital insights into mechanisms involved in the resistance of solid tumors to those therapeutics, however, tools to quantify in situ drug exposure are few. We have investigated the potential of programmed death ligand- 1 (PD-L1) pharmacodynamics, quantified using positron emission tomography (PET), to inform on the tumor exposure of anti-PD-L1 therapeutics. Experimental Design: To non-invasively quantify PD-L1 levels, we first developed a novel peptide-based gallium-68 labeled binder, [68Ga]Ga-DK223, and evaluated its in vivo distribution, pharmacokinetics, and PD-L1 specificity in preclinical models of triple-negative breast cancer (TNBC) and urothelial carcinoma (UC) with variable PD-L1 expression. We then quantified baseline and accessible PD-L1 levels in tumors as a non-invasive pharmacodynamic measure to assess tumor exposure to two anti-PD-L1 antibodies (avelumab and durvalumab). Results: DK223 exhibited a KD of 1.01±0.83 nM for PD-L1 and inhibited the PD-1:PD-L1 interaction in a dose-dependent manner. [68Ga]Ga-DK223 provides high-contrast PET images within 60 min of administration and detects PD-L1 in an expression-dependent manner in xenograft models. PD-L1 pharmacodynamics measured using [68Ga]Ga-DK223-PET revealed that avelumab and durvalumab had similar exposure early during therapy, but only durvalumab exhibited sustained exposure at the tumor. Conclusions: [68Ga]Ga-DK223 detected variable PD-L1 levels and exhibited salient features required for clinical translation. [68Ga]Ga-DK223-PET could be useful for quantifying total PD-L1 levels at baseline and accessible PD-L1 levels during therapy to understand drug exposure at the tumor, thus supporting its use for guiding and optimizing ICT.
🪵Attention🪓
🐘For all of those who have made #Mastodon accounts, follow #TumorBoardTuesday!!
🐘We’re learning!
🐘We’re trying to connect with the #Oncology #Oncodon community!
🐘We have NO intentions of leaving #MedTwitter!!
https://mstdn.science/web/@TumorBoardTuesday#
@freddyeescorcia
485 Posts, 153 Following, 95 Followers · Online Tumor Board with a molecular angle ~ Join us every Tuesday 8pm ET for discussions, polls, & mini tutorials • Created by Dr Mike Pishvaian (@MPishvaian) • Assisted by Alison Rothbaum (@EmpoweringPts9) & Dr John Ebben (@JohnEbbenMDPhD) • FREE #CME • #TumorBoard #Oncology #Oncodon #Medodon #MedMastodon #TumorBoardTuesday #PrecisionMedicine #Cancer
I have so many ideas going on in my head, is there a way to keep all of it and not forgetting?
TumorBoardTuesday
Freddy E Escorcia 
Susan Egbert, PharmD